Aurobindo Pharma USA secures FTC clearance for $250 million Lannett acquisition

Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility

Punita Kumar-Sinha appointed Independent Director at Aurobindo Pharma USA

Seasoned governance expert and board leader brings extensive experience in strategic oversight, risk management, and corporate governance across multiple sectors

Aurobindo Pharma receives USFDA nod for generic Tofacitinib tablets

Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval

Aurobindo Pharma launches TheraNym, India’s largest biologics CMO

MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market

Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore

Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore

Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid

The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics

Aurobindo Pharma wins key FDA nod for $138M US cough drug market entry

The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation

Aurobindo Pharma wins USFDA nod for rare disease drug set for immediate launch

Aurobindo Pharma wins USFDA approval for generic Xigduo XR

Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually

Aurobindo Pharma’s CuraTeQ achieves Phase 3 success for Omalizumab biosimilar

The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline